You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.

Are you sure you want to leave?



Watch highlights of our 2019 ERA–EDTA educational symposium

25 August 2019

Vifor Pharma made an impact at ERA–EDTA 2019

From 13 June to 16 June 2019, Vifor Pharma was at the 56th ERA–EDTA Congress in Budapest, Hungary. We hosted a disease state education booth and sponsored an educational symposium with the aim of enhancing awareness of secondary hyperparathyroidism (SHPT) and the limitations of current treatments.

Our booth sparked intense debates

Physicians who visited our booth, which we set up in one of the e-campus learning stations, were able to:

  • See how up-to-date their SHPT knowledge was by taking the SHPT Challenge (an interactive challenge that tests physicians’ understanding of SHPT and its treatment) 
  • Watch our animation on the unmet needs of SHPT treatment (which you can view right now on our Watch page)
  • Take hard copies of two of our leaflets: ‘Unmet Needs in SHPT Treatment’ and ‘KDIGO CKD–MBD Quick Reference Guide’ (which you can find on our Download page)

The booth was a success, attracting lots of attention and stimulating passionate discussions.

Our educational symposium was a hit

Entitled ‘Navigating CKD–MBD in 2019: expert perspectives’, the symposium was chaired by Professor Jordi Bover* and attracted a very attentive audience.

Consisting of two presentations, the symposium began with an introduction from Professor Bover, who outlined SHPT and its pathogenesis. This was followed by the first presentation, delivered by Professor Markus Ketteler, who explored the current concepts and controversies inherent to the management of SHPT in both predialysis and dialysis patients.

The second presentation was given by Associate Professor Marc Vervloet, who considered the challenges associated with the management of hyperphosphataemia, including appropriate phosphate targets and current and future strategies that may help patients achieve them.

Watch the highlights now

If you missed the symposium, you can watch the highlights below.


*Clinical Professor of Nephrology; Nephrology Department, Fundació Puigvert, Universitat Autònoma de Barcelona; Catalonia, Spain.

Head of General Internal Medicine and Nephrology; Robert-Bosch-Krankenhaus; Stuttgart, Germany.

Associate Professor; Department of Nephrology, VU University Medical Center; Amsterdam, the Netherlands